| | Characteristic | (%) |
| | Sex (men) | 48 (55.8) | | Age (years), median (interval) | 52 (17-82) | | <30 years | 10 (11.6) | | 30–45 years | 23 (26.7) | | 46–60 years | 21 (24.4) | | >60 years | 32 (37.2) | | Immunophenotype | | Undifferentiated acute myeloblastic (M0) | 8 (9.3) | | AML with minimal maturation (M1) | 13 (15.1) | | AML with maturation (M2) | 13 (15.1) | | Acute myelomonocytic leukemia (M4) | 4 (4.7) | | Acute monocytic leukemia (M5) | 21 (24.4) | | AML, not specified (NOS) | 14 (16.3) | | AML and MDS, therapy related | | AML with characteristics of MDS | 10 (12.0) | | AML secondary to chemotherapy | 3 (3.5) | | Karyotype | | Normal | 42 (48.8) | | Abnormal | 25 (29.1) | | No growth | 7 (8.1) | | Not requested | 12 (14.0) | | Cytogenetic/molecular alterations | 28 (32.6) | | FLT3 ITD | 4 (14.2) | | NMP1 | 1 (3.6) | | FLT3 ITD with NMP1 | 3 (10.7) | | t(9;22)(q34.1;q11.2) | 1 (3.6) | | Del 5q | 3 (10.7) | | 46 XX -7 +7q- (Del7q) | 1 (3.6) | | 46 XY, right (16)(17) | 1 (3.6) | | 46 XY, -10, +10 | 1 (3.6) | | 45 XY, t(14p17p), -14,-17 | 1 (3.6) | | Trisomy 8 | 4 (14.2) | | Trisomy 12 | 1 (3.6) | | +6 +8 +12 | 1 (3.6) | | 46, XY/49, XY, -1, -4, -5, -11, -12, 17, +mar,+mar,+mar,+mar.+mar,+mar,+mar,+mar,+mar | 1 (3.6) | | Inv (16) | 1 (3.6) | | t (8;21) (q22;q22.1) | 4 (14.2) | | Cytogenetic risk | | Adverse | 19 (22.1) | | Intermediate | 43 (50.0) | | Favorable | 6 (7.0) | | Undetermined | 18 (20.9) | | WBC count (mm3), median (interval) | 35090 (500-298400) | | Hemoglobin (g/dl), median (interval) | 8.85 (3.2-16.06) | | Platelet count (mm3), median (interval) | 79460 (2800-570000) |
|
|
